There have been significant changes in the CLL treatment landscape with the approval of novel targeted therapies and greater understanding of how molecular and mutation status can guide treatment decisions. CARE™ Faculty recently spoke with CLL expert, Dr. Paolo Ghia (Milan, Italy) to get a global perspective on these advances and how they have impacted his practice.
This is the second issue of a CARE™ Global Interview series and covers content on:
1. Frontline CLL
• Factors that affect treatment choice
• Implications of recent data
• Novel management approaches
2. Sequencing Novel Agents